NASDAQ:LGND - Ligand Pharmaceuticals Stock Price, Forecast & News

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) posted its quarterly earnings results on Thursday, February, 6th. The biotechnology company reported $0.71 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.07. The biotechnology company had revenue of $27 million for the quarter, compared to the consensus estimate of $25.30 million. Ligand Pharmaceuticals had a return on equity of 4.34% and a net margin of 523.19%. The firm's quarterly revenue was down 54.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.70 EPS. View Ligand Pharmaceuticals' Earnings History.

Ligand Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for Ligand Pharmaceuticals.

Ligand Pharmaceuticals issued an update on its FY20 earnings guidance on Thursday, February, 6th. The company provided earnings per share (EPS) guidance of Approx $3.40 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.49. The company issued revenue guidance of Approx $121 million, compared to the consensus revenue estimate of $126.51 million.

5 equities research analysts have issued 1-year price objectives for Ligand Pharmaceuticals' shares. Their forecasts range from $132.00 to $237.00. On average, they expect Ligand Pharmaceuticals' stock price to reach $164.80 in the next year. This suggests a possible upside of 62.5% from the stock's current price. View Analyst Price Targets for Ligand Pharmaceuticals.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ligand Pharmaceuticals.

News stories about LGND stock have trended extremely negative this week, according to InfoTrie. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ligand Pharmaceuticals earned a media sentiment score of -4.6 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Ligand Pharmaceuticals.

Some companies that are related to Ligand Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Illumina (ILMN), Netflix (NFLX), Gilead Sciences (GILD), AbbVie (ABBV), Intel (INTC) and salesforce.com (CRM).

Ligand Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (10.35%), William Blair Investment Management LLC (8.07%), Renaissance Technologies LLC (5.81%), Conestoga Capital Advisors LLC (3.53%), Thrivent Financial for Lutherans (3.01%) and Rice Hall James & Associates LLC (1.72%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Stephen L Sabba, Sunil Patel and Todd C Davis. View Institutional Ownership Trends for Ligand Pharmaceuticals.

LGND stock was sold by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Renaissance Technologies LLC, AJO LP, Victory Capital Management Inc., Victory Capital Management Inc., AQR Capital Management LLC, Sei Investments Co. and CIBC Private Wealth Group LLC. View Insider Buying and Selling for Ligand Pharmaceuticals.

LGND stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Thrivent Financial for Lutherans, William Blair Investment Management LLC, California Public Employees Retirement System, KBC Group NV, Eaton Vance Management, Tygh Capital Management Inc. and Credit Suisse AG. Company insiders that have bought Ligand Pharmaceuticals stock in the last two years include Jason Aryeh, John L Higgins and Sunil Patel. View Insider Buying and Selling for Ligand Pharmaceuticals.

Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LGND stock can currently be purchased for approximately $101.39.

Ligand Pharmaceuticals has a market capitalization of $1.78 billion and generates $120.28 million in revenue each year. The biotechnology company earns $629.30 million in net income (profit) each year or $2.11 on an earnings per share basis. Ligand Pharmaceuticals employs 116 workers across the globe.View Additional Information About Ligand Pharmaceuticals.

The official website for Ligand Pharmaceuticals is http://www.ligand.com/.

Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected]